Shearman & Sterling has advised Hong Kong-listed healthcare company Golden Meditech on the $830 million sale of its stake in NYSE-listed China Cord Blood, represented by Zhong Lun. The buyer was Nanjing Yingpeng Huikang Medical Industry Investment Partnership.  

China Cord Blood is a provider of cord blood processing and storage services and is said to be the largest cord blood banking operator in China. 

The Shearman & Sterling team was led by partner Paul Strecker.